AU2003249983A1 - Piperidines useful for the treatment of central nervous system disorders - Google Patents
Piperidines useful for the treatment of central nervous system disordersInfo
- Publication number
- AU2003249983A1 AU2003249983A1 AU2003249983A AU2003249983A AU2003249983A1 AU 2003249983 A1 AU2003249983 A1 AU 2003249983A1 AU 2003249983 A AU2003249983 A AU 2003249983A AU 2003249983 A AU2003249983 A AU 2003249983A AU 2003249983 A1 AU2003249983 A1 AU 2003249983A1
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- nervous system
- central nervous
- system disorders
- piperidines useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP0208002 | 2002-07-18 | ||
EPPCT/EP02/08002 | 2002-07-18 | ||
PCT/EP2003/007298 WO2004009549A2 (en) | 2002-07-18 | 2003-07-08 | Piperidines useful for the treatment of central nervous system disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003249983A1 true AU2003249983A1 (en) | 2004-02-09 |
AU2003249983A8 AU2003249983A8 (en) | 2004-02-09 |
Family
ID=30470214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003249983A Abandoned AU2003249983A1 (en) | 2002-07-18 | 2003-07-08 | Piperidines useful for the treatment of central nervous system disorders |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003249983A1 (en) |
WO (1) | WO2004009549A2 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60125335T2 (en) | 2000-03-06 | 2007-07-12 | Acadia Pharmaceuticals Inc., San Diego | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES |
CN101050215A (en) | 2001-12-28 | 2007-10-10 | 阿卡蒂亚药品公司 | Spiroazacyclic compounds as monoamine receptor modulators |
IL165907A0 (en) | 2002-06-24 | 2006-01-15 | Acadia Pharm Inc | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
NZ544046A (en) | 2003-06-17 | 2009-08-28 | Pfizer | N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors |
WO2005019176A1 (en) * | 2003-08-25 | 2005-03-03 | Actelion Pharmaceuticals Ltd | Substituted amino-aza-cyclohexanes |
EP1680109A4 (en) | 2003-10-07 | 2009-05-06 | Renovis Inc | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
EP2289879B1 (en) | 2004-09-27 | 2014-11-12 | Acadia Pharmaceuticals Inc. | Synthesis of a crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt |
TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
JP5281794B2 (en) | 2005-10-25 | 2013-09-04 | 塩野義製薬株式会社 | Aminodihydrothiazine derivatives |
US8247442B2 (en) | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
TW200815353A (en) | 2006-04-13 | 2008-04-01 | Euro Celtique Sa | Benzenesulfonamide compounds and their use |
US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | Pharmaceutical composition for treatment of alzheimer's disease |
WO2008133274A1 (en) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with cyclic groups |
US8853392B2 (en) | 2007-06-03 | 2014-10-07 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
WO2008151184A1 (en) * | 2007-06-03 | 2008-12-11 | Vanderbilt University | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
CN102119161B (en) | 2008-06-13 | 2015-07-08 | 盐野义制药株式会社 | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
JPWO2010047372A1 (en) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | 2-Aminopyrimidin-4-one and 2-aminopyridine derivatives having BACE1 inhibitory activity |
RU2012129168A (en) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | OXASINE DERIVATIVES |
EP2634188A4 (en) | 2010-10-29 | 2014-05-07 | Shionogi & Co | Fused aminodihydropyrimidine derivative |
JP5816630B2 (en) | 2010-10-29 | 2015-11-18 | 塩野義製薬株式会社 | Naphthyridine derivatives |
JPWO2012147763A1 (en) | 2011-04-26 | 2014-07-28 | 塩野義製薬株式会社 | Oxazine derivatives and BACE1 inhibitors containing the same |
WO2013056054A2 (en) * | 2011-10-14 | 2013-04-18 | Genentech, Inc | Peptide inhibitors of bace1 |
EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
SG10202110242YA (en) * | 2015-09-16 | 2021-10-28 | Metacrine Inc | Farnesoid x receptor agonists and uses thereof |
EP3349743B1 (en) * | 2015-09-18 | 2022-04-06 | St. Jude Children's Research Hospital | Methods and compositions of inhibiting dcn1-ubc12 interaction |
US10961198B2 (en) | 2017-03-15 | 2021-03-30 | Metacrine, Inc. | Farnesoid X receptor agonists and uses thereof |
JP7258763B2 (en) | 2017-03-15 | 2023-04-17 | メタクリン,インク. | Farnesoid X receptor agonists and uses thereof |
KR20210076910A (en) | 2018-09-18 | 2021-06-24 | 메타크린, 인크. | Farnesoid X receptor agonists and uses thereof |
CN112480066B (en) * | 2020-11-27 | 2021-08-31 | 太原理工大学 | Schiff base multifunctional fluorescent probe and preparation method and application thereof |
CN114763335A (en) * | 2021-01-15 | 2022-07-19 | 江苏谛奇医药科技有限公司 | 4-amide piperidine derivative and preparation method and application thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE812911C (en) * | 1945-03-12 | 1951-09-06 | Rhone Poulenc Sa | Process for the preparation of new substituted derivatives of piperidine |
JPH0873455A (en) * | 1994-03-15 | 1996-03-19 | Upjohn Co:The | Oxazolidinone derivative and medicine composition containingit as effective component |
KR960007560A (en) * | 1994-08-16 | 1996-03-22 | 김정규 | Novel amine derivatives, their preparation and use as antiarrhythmics |
DE19643331A1 (en) * | 1996-10-21 | 1998-04-23 | Thomae Gmbh Dr K | 1- (4-Piperidinyl) -piperidinylenes, medicaments containing these compounds, their use and process for their preparation |
AU775123B2 (en) * | 1999-03-24 | 2004-07-15 | Anormed Inc. | Chemokine recpetor binding heterocyclic compounds |
FR2802206B1 (en) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | 4-AMINOPIPERIDINE DERIVATIVES AND THEIR USE AS MEDICINAL PRODUCTS |
DE60125335T2 (en) * | 2000-03-06 | 2007-07-12 | Acadia Pharmaceuticals Inc., San Diego | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES |
EP1296950A2 (en) * | 2000-04-20 | 2003-04-02 | NPS Allelix Corp. | Aminopiperidines for use as glyt-1 inhibitors |
JP2004509866A (en) * | 2000-09-25 | 2004-04-02 | アクテリオン ファマシューティカルズ リミテッド | Substituted amino-aza-cycloalkanes |
US6395753B1 (en) * | 2001-08-30 | 2002-05-28 | Kowa Co., Ltd. | Cyclic amine compounds and pharmaceutical composition containing the same |
WO2003037271A2 (en) * | 2001-10-30 | 2003-05-08 | Millennium Pharmaceuticals,Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
-
2003
- 2003-07-08 AU AU2003249983A patent/AU2003249983A1/en not_active Abandoned
- 2003-07-08 WO PCT/EP2003/007298 patent/WO2004009549A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2004009549A2 (en) | 2004-01-29 |
WO2004009549A3 (en) | 2004-06-03 |
AU2003249983A8 (en) | 2004-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003249983A1 (en) | Piperidines useful for the treatment of central nervous system disorders | |
IL176581A0 (en) | Immunomodulatory compounds for the treatment of central nervous system disorders | |
EP1434801A4 (en) | Treatment for central nervous system disorders | |
AU2003286567A1 (en) | Methods for the treatment of skin disorders | |
PL372425A1 (en) | Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders | |
IL175055A0 (en) | Combinations useful for the treatment of neuronal disorders | |
AU2003297761A1 (en) | Methods for treating neurological language disorders | |
EP1471909A4 (en) | Pharmaceutical composition and method for treating disorders of the central nervous system | |
IL164857A0 (en) | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | |
ZA200601973B (en) | Methods and reagents for the treatment of immuno-inflammatory disorders | |
IL169091A0 (en) | Benzazepine derivatives for the treatment of neurological disorders | |
AU2003274342A1 (en) | Compositions for the treatment of autoimmune disorders | |
AU2002356525A1 (en) | Substituted amines for the treatment of neurological disorders | |
AU2003210597A1 (en) | Methods for treating eye disorders | |
AU2003291719A1 (en) | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders | |
AU2003286728A1 (en) | Compounds for the treatment of metabolic disorders | |
AU6910600A (en) | Methods for the treatment of mental disorders | |
AU2003293099A1 (en) | Treatment of dna damage related disorders | |
AU2003298913A1 (en) | Treatment of inflammatory disorders with 2,3-benzodiazepines | |
AU2003205898A1 (en) | Combination therapy for respiratory disorders | |
HRP20041160A2 (en) | Novel combination for the treatment of airway disorders | |
AU2003237460A1 (en) | Combination treatments for purinoceptor-related disorders | |
AU2002258798A1 (en) | Methods for the treatment of hepatic disorders | |
AU2003274885A1 (en) | Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders | |
AU2003243214A1 (en) | Salts of bis-arylsulfones for the treatment of cns disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |